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Background: Atorvastatin is a potent inhibitor of the mevalonate pathway and widely used as a hypolipidemic
drug. Some epidemiological studies and animal experiments indicate that the long-term use of atorvastatin and
structurally related drugs might be associated with a reduced risk of developing hepatocellular carcinoma (HCC),
the most common hepatocellular malignancy in humans. However, the potential of atorvastatin to inhibit HCC
formation is controversially discussed.
Methods: Hepatocellular tumors were chemically induced by treatment of C3H/He mice with 10 μg/g body
weight N-nitrosodiethylamine and the ability of atorvastatin to interfere with tumor formation was investigated
by treatment of mice with 0.1% atorvastatin in the diet for 6 months. Tumor size and tumor multiplicity were
analyzed, as were tissue levels of cholesterol and atorvastatin.
Results: Atorvastatin treatment efficiently reduced serum cholesterol levels. However, the growth of tumors
driven by activated MAPK (mitogen-activated protein kinase) signaling was not attenuated by the presence of
the drug, as evidenced by a lack of reduction of tumor volume or tumor multiplicity by atorvastatin. Levels of
the atorvastatin uptake transporters Oatp1a4 and Oatp1b2 were down-regulated at the mRNA and protein levels
in chemically induced mouse liver tumors, but without striking effects on atorvastatin concentrations in the
tumor tissue.
Conclusion: In summary, the present data provide substantial evidence that atorvastatin does not beneficially
influence tumor growth in mouse liver and thereby challenge the hypothesis that statin use might protect
against hepatocellular cancer.
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Statins are an important and widely used class of hypolipid-
emic drugs. Their pharmacological efficacy is based on their
ability to competitively inhibit 3-hydroxy-3-methyl-glutaryl-
CoA reductase (HMGCR), an important and rate-limiting
enzyme in the isoprenoid- and cholesterol-synthesizing
mevalonate pathway. Apart from their lipid-lowering
properties, several epidemiological studies evidence that
the long-term use of statins in humans might be causally
linked to a reduced risk of developing different types of
cancer. For recent review articles about this topic see for
example [1-4]. However, there are also studies available* Correspondence: albert.braeuning@uni-tuebingen.de
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article, unless otherwise stated.which negate the beneficial effects of statin use on cancer
incidence or mortality [5,6]. Another meta-analysis of
published data came to the conclusion that there is only
weak, inconclusive evidence for a beneficial effect of statin
use regarding cancer development [7].
One organ, for which anti-cancer effects of statins
have been discussed quite often, is the liver. A number
of epidemiological studies and meta-analyses have been
published linking statin treatment to a diminished risk
for hepatocellular carcinoma (HCC) [8-15]. However,
epidemiological evidence for the inhibition of HCC for-
mation by statins is controversial, due to potential con-
founders, bias, controversies about study design, mechanistic
issues, and absence of a duration-risk relationship [10,16-20].
In vitro, different statins are able to inhibit the growth and to
induce apoptosis and cell cycle arrest of hepatoma cell linestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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HUH-7-derived xenograft tumors [24]. Several genetic or
chemical experimental HCC models have been used to
analyze potential tumor-inhibiting properties of statins in ro-
dents: transgenic, MYC-driven HCC development was di-
minished by treatment with atorvastatin [25], as rosuvastatin
did in mice developing HCC due to transgenic SV40-T anti-
gen expression [26]. Diethylnitrosamine (DEN)-induced liver
tumors in obese mice were suppressed by treatment with
pitavastatin [27], and similar effects were observed in DEN-
treated rats when lovastatin was co-administered [28]. By
contrast, no tumor-inhibitory effect of atorvastatin was de-
tectable on the development of murine TSC2-associated liver
hemangiosarcomas [29].
In consideration of ambiguous epidemiological data
and of the fact that different statins produce highly di-
vergent effects on hepatoma cells [30], further animal
experiments with different statins and HCC models are
needed. Therefore, in the present study, we analyzed po-
tential protective effects of atorvastatin treatment on the
growth of chemically induced mouse liver tumors har-
boring an activated Ras/Raf/MAPK (mitogen-activated
protein kinase) signaling pathway. This type of tumors
was chosen because the MAPK is frequently overacti-
vated in human HCC [31] and because previous studies
by our group revealed that enzymes of cholesterol
biosynthesis, namely Hmgcs1 (3-hydroxy-3-methylglutaryl-
CoA synthase) and Lss (lanosterol synthase), are transcrip-
tionally up-regulated in chemically induced mouse liver
tumors with an activated Ras/Raf/MAPK pathway. In
addition, a down-regulation of Cyp7a1, encoding the
rate-limiting enzyme in the cholesterol-metabolizing
bile acid synthesis pathway, was observed in these tu-
mors and accordingly, tumors with activated MAPK
signaling contained significantly higher levels of chol-
esterol [32,33]. Assuming the observed changes in the
tumor’s metabolic profile being advantageous for its
growth or survival, inhibitors of cholesterol biosyn-
thesis might be especially suited as a treatment option
for this particular liver tumor phenotype.
Methods
Animal experiment
Male inbred C3H/HeN mice (Janvier Labs, Saint-Berthevin,
France) were injected with a single i.p. dose of 10 μg/g body
weight of the genotoxic tumor inducer DEN (dissolved in
0.9% NaCl) at 12–14 days of age. In the course of hepatic
DEN metabolism, ethyl cations are formed which form
covalent adducts with the DNA, thus giving rise to
gene mutations. This procedure follows an established
protocol as used e.g. in [32-34], and the resulting tumor
phenotype has been extensively studied [33,34]. One week
later, animals were stratified into two groups: one group
(25 mice) received standard control diet (Ssniff, Soest,Germany), the second group (24 mice) was fed a modified
diet (Ssniff) containing 0.1% wt/wt atorvastatin (Ca2+ salt,
catalog no. A2476; TCI, Tokyo, Japan). Atorvastatin was
chosen because it is the most commonly prescribed and
also one of the most potent statins on the market. The se-
lected concentration of the drug has proven to be effica-
cious to reduce cholesterol levels in mice without exerting
toxic effects [29]. Mice had access to food and tap water
ad libitum and were kept on a 12 h dark/light cycle. After
6 months of continuous atorvastatin treatment, the mice
were killed; livers were excised and immediately frozen on
dry ice for immunohistochemistry. Aliquots of livers and
serum samples to be used for cholesterol determination
were snap-frozen in liquid nitrogen. All animals received
humane care and protocols complied with institutional
guidelines. Ethical approval for the animal study was ob-
tained from the Regierungspräsidium Tübingen (permis-
sion no. TO6/10).Immunohistochemical staining
Cryostat sections (10 μm thickness) were fixed in 4% para-
formaldehyde and stained with hematoxylin/eosin or immu-
nohistochemically for glutamine synthetase, E-cadherin, and
phosphorylated ERK1/2 (extracellular signal-regulated kin-
ase) using the antibodies and methodology described in
previous papers [33,35]. For staining of OATP1A4 and
OATP1B2, primary antibodies against the two transporters
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; catalog
no. sc-47270 and sc-18436) were used at 1:50 dilution
in combination with horseradish peroxidase-conjugated
donkey-anti-goat secondary antibodies (1:50 dilution;
Santa Cruz Biotechnology; catalog no. sc-3851) and
the substrates 3-amino-9-ethylcarbazole/H2O2. Histochem-
ical staining for glucose-6-phosphatase activity was per-
formed according to [36] on glutaradehyde-fixed slices.Western blotting
Whole cell extracts were denatured in Laemmli buffer at
40°C, separated by sodiumdodecylsulfate-polyacrylamide
gel electrophoresis (SDS-PAGE; 50 μg of protein per
lane) and transferred to PVDF membranes. Antibodies
against E-cadherin (1:100; Becton Dickinson, Heidelberg,
Germany; catalog no. 610181), OATP1A4 and OATP1A2
(see above; 1:200 dilution), and glyceraldehyde-3-phosphate
dehydrogenase (1:1,000; Millipore, Chandler’s Ford, UK;
catalog no. MAB374) were used in combination with alka-
line phosphatase-conjugated secondary antibodies directed
against mouse (1:10,000; Tropix, Weiterstadt, Germany;
catalog no. AC32ML) or goat immunoglobulins (1:5,000;
Santa Cruz Biotechnology; catalog no. sc-2022), with CDP-
Star (Tropix) as a substrate. Chemiluminescence was mon-
itored on a charge-coupled device (CCD) camera system
(Raytest, Straubenhardt, Germany).
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Serum cholesterol was determined by GC-MS as described
previously [37] with minor modifications: briefly, 10 μl of
serum were spiked with 10 μg of [2H5]-cholesterol as in-
ternal standard. After saponification with 0.5 ml 1 M NaOH
in 90% ethanol at 70°C for 1 h, 250 μl H2O were added and
the samples extracted with 2 ml n-hexane. A 50 μl aliquot
of the extract was evaporated to dryness and derivatized
with 20 μlN,O-bis(trimethylsilyl)trifluoroacetamide for
30 min at room temperature.
Sample preparation for 4β-hydroxycholesterol analysis
was performed as previously published [38] with minor
modifications. Briefly, liver tissue (10–30 mg) was ho-
mogenized in 400 μl phosphate buffer (0.1 M potassium
phosphate, 2 mM EDTA, 11 μg/ml butylhydroxytoluene
(BHT), pH 7.4) using a pestle. After addition of 10 μg
BHT and 50 ng of the internal standard [2H4]-4β-hydroxy-
cholesterol, the homogenate was saponified with 2.5 ml
1 M NaOH in 90% ethanol at 70°C for 1 h under argon
and then extracted with 1 ml H2O and 5 ml CHCl3. The
organic phase was evaporated to dryness in a stream of N2
and the residue dissolved in 1 ml toluene. Samples were
purified by solid phase extraction on silica cartridges
(Isolute Si 100 mg; Biotage, Uppsala, Sweden) precon-
ditioned with n-hexane. Cartridges were washed with 1 ml
n-hexane and 10 ml 2-propanol in n-hexane (0.5% v/v), and
then eluted with 2 ml 2-propanol in n-hexane (30% v/v).
The eluate was evaporated to dryness in a stream of N2 and
derivatized as described above.
Cholesterol and 4β-hydroxycholesterol quantification
A 5975C inert XL MSD in the EI mode, coupled to a 7890A
gas chromatograph (GC; Agilent Technologies, Waldbronn,
Germany) was used. GC was performed on a J&W DB-5MS
column (25 m, 0.2 mm i.d., 0.33 μm film thickness; Agilent)
in the splitless mode. For cholesterol analysis, the GC oven
program started at 150°C and was held for 1 min.
Temperature was increased with 20°C/min to 300°C,
with a total run time of 18.5 min. The trimethylsilyl de-
rivatives of cholesterol and the internal standard [2H5]-
cholesterol were detected in SIM mode at m/z 458 and
463, respectively. For the analysis of 4β-hydroxycholesterol,
the GC oven program started at 150°C and was held for
1 min. Temperature was increased with 10°C/min to
250°C, then with 30°C/min to 300°C. The trimethylsilyl
derivatives of 4β-hydroxycholesterol and the internal
standard [2H4]-4β-hydroxycholesterol were quantified
in SIM mode at m/z 366 and 370, respectively, using
m/z 456 and 460 as qualifier ions.
Calibration samples for cholesterol were prepared in isooc-
tane with 10% 2-propanol in the concentration range from
1 μg to 30 μg. Calibration samples for 4β-hydroxycholesterol
were prepared in isooctane with 0.8% 2-propanol from 5 ng
to 100 ng.Calibration samples were worked up as the samples,
and analyzed together with the unknown samples. Cali-
bration curves based on internal standard calibration
were obtained by weighted (1/×) linear regression for
the peak area ratio of the analyte to the respective in-
ternal standard against the amount of the analyte. The
concentration in unknown samples was obtained from
the regression line.Atorvastatin and 2-hydroxy-atorvastatin quantification
Tissue samples (50 to 150 mg) were homogenized in a
total volume of 600 μl of acetate buffer (0.1 M, pH 5)
and internal standard (100 pmol each of 2H5-atorva-
statin and 2H5-2-hydroxyatorvastatin) in a FastPrep 24
homogenizer (MP Biomedicals, Santa Ana, USA) for 40s
at speed 6.0 using lysing matrix D. The homogenate was
extracted with ether:2-propanol 9:1 (v/v), and the or-
ganic phase evaporated in a stream of nitrogen. The residue
was dissolved in aqueous ammonium acetate (10 mM with
1% formic acid):acetonitrile 60:40 (v/v) and determined by
LC/MS-MS analysis as described [39].Quantification of tumor burden
Tumor burden was quantified as the area fraction (corre-
sponding to the volume fraction) of glucose-6-phosphatase-
altered lesions on an Axio Imager light microscope (Imager.
M1; Zeiss, Göttingen, Germany). AxioVision software
Rel.4.5 (Zeiss) was used to determine tumor and nor-
mal tissue areas. The calculation of the number and
size of glucose-6-phosphatase lesions per cm3 of liver
tissue was performed according to [40]. For each
mouse, three liver lobes were examined (right lobe, left
lateral lobe, and caudate lobe) using three slices per
liver lobe with at least 20 sections distance between
the individual slices. Hematoxylin/eosin staining of the
tumors and immunohistochemical staining for glutam-
ine synthetase and E-cadherin was assessed on parallel
slices.Mutation analysis
Tumor tissue samples from mice of both treatment
groups were punched out of liver slices (20 μm thickness)
by a sharpened cannula. Following proteinase K digestion,
genomic DNA was amplified by polymerase chain reac-




GTTCTGGAACTATATAGACAG-3′. PCR products were
analyzed for mutations in Codon 61 of Ha-ras and Codon
637 of B-raf by restriction fragment length polymor-
phisms analysis as previously described [41].
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Mouse hepatoma cell lines 53.2b, 55.1c, 70.4 and Hepa1c1c7
[42] were grown in D-MEM/F-12 medium (Invitrogen,
Darmstadt, Germany) supplemented with 1% fetal bovine
serum and antibiotics. For cytotoxicity testing, 9000 cells
were seeded per well of a 96-well plate and treated with the
indicated concentrations of atorvastatin for 24 h starting
24 h after seeding. Plates were analyzed using the neutral
red uptake and Alamar Blue tests as previously described
[43]. For the analysis of growth behavior, cells were seeded
on 96 well-plates at a density of 5000 cells/well and treated
with the indicated concentrations of atorvastatin starting
12 h after seeding. Solvent controls received medium con-
taining 0.4% dimethyl sulfoxide. Medium was changed after
48 h. Following different incubation periods, cells were fixed
by 10% trichloroacetid acid and analyzed photometrically
after staining with sulforhodamine B according to [44].
Gene expression analysis
Total RNA was isolated and reverse transcribed from
cell cultures or liver tissue as previously described [42],
using Trizol reagent (Invitrogen) and avian myeloblasto-
sis virus reverse transcriptase (Promega, Mannheim,
Germany). SYBR green I-based analyses of target gene
expression were conducted on a LightCycler instrument
(Roche) as previously described [42] using the following




CCGTAAGAG-3′; Oatp1a4_fwd 5′- GAAACAGTATT
CCTCCACCATC-3′, Oatp1a4_rev 5′-TTGATAAGCCC
AACTACAGACG-3′; Oatp1b2_fwd 5′-ATCCCGTGAC
TAATCCAACA-3′, Oatp1b2_rev 5′- ACCAAACTGCT
GCTCTATAAACT-3′; 18S rRNA_fwd 5′-CGGCTAC
CACATCCAAGGAA-3′, 18S rRNA_rev 5′-GCTGGAA
TTACCGCGGCT-3′. The Mm_Cyp7a1_1_SG Quanti-
Tect Primer Assay (Qiagen, Hilden, Germany) was used for
Cyp7a1 determination. Expression was normalized to the
housekeeping gene 18S rRNA using the Pfaffl method [45].
Calculation of statistical significance
Statistical significance was calculated using an unpaired
t-test with Welch’s correction. Homogeneity of variances
was tested for using Bartlett’s test. The Shapiro-Wilk test
was used to analyze normal distribution of values. Dif-
ferences were considered significant when p < 0.05.
Results
Growth inhibition of murine tumor cell lines by
atorvastatin in vitro
First, studies with mouse hepatoma cell lines were con-
ducted to prove the in vitro efficacy of atorvastatin treat-
ment of murine liver tumor cells. Mouse hepatoma celllines 53.2b, 55.1c, 70.4, and Hepa1c1c7 were screened
for their expression of Hmgcs1 and Hmgcr, encoding the
first and rate-limiting steps in cholesterol biosynthesis.
All cell lines expressed the two mRNAs at levels com-
parable or slightly higher than normal mouse liver.
Cyp7a1 expression was not detectable (data not shown).
A moderate therapeutic dose of 40 mg atorvastatin
per day results in maximum human plasma levels of
66 ng/ml, corresponding to a plasma concentration
of ~118 nM of the drug [46]. However, hepatic con-
centrations are ~50-fold higher than in plasma, as mea-
sured in atorvastatin-treated rats, resulting in an estimated
liver concentration of ~6 μM [47]. Therefore, the ability of
atorvastatin to interfere with hepatoma cell growth in vitro
was tested at concentrations ranging from 1 μM to 20 μM,
in order to meet the expected in vivo concentration of
atorvastatin in mouse liver tumor cells. After 24 h of treat-
ment, 55.1c cells appeared to be rather resistant to atorva-
statin treatment up to the maximum concentration of
20 μM, while cells from lines 70.4 and Hepa1c1c7 showed
the greatest sensitivity (Figure 1A). Long-term growth of
atorvastatin-treated cells was monitored using the sulfor-
hodamine B assay. Again, 55.1c cells were most resistant,
with only the highest concentration of atorvastatin
causing a remarkable inhibition of cell growth (Figure 1B).
Hepa1c1c7 cells showed diminished growth already at
1 μM atorvastatin, while 53.2b cells were inhibited at con-
centrations ≥5 μM. In summary, atorvastatin was able
to interfere with the viability and/or growth of differ-
ent mouse hepatoma cell lines at in vivo-relevant
concentrations.
Effects of atorvastatin on hepatoma growth in vivo
Chemically induced mouse liver tumors were generated
by a single injection of DEN at 2 weeks of age according
to [34]. Starting one week later, mice were stratified into
a control (standard diet) and an atorvastatin group (0.1%
atorvastatin in the diet). Atorvastatin feeding slightly but
significantly inhibited weight gain of the animals in the
atorvastatin group during the 6 months period of the ex-
periment (Figure 2A). Atorvastatin-fed mice possessed
larger livers and had an increased liver to body weight
ratio (Figure 2B). In line with its expected pharmaco-
logical effects, atorvastatin significantly reduced serum chol-
esterol and liver 4β-hydroxycholesterol levels (Figure 2C).
None of the animals died during the study or had to be
sacrificed ahead of schedule.
At the end of the experiment, livers were isolated and the
occurrence of hepatocellular tumors was analyzed. Three
liver lobes were analyzed for each mouse (see Methods sec-
tion). Tumor incidence was 100% in both groups and mul-
tiple tumors were detected per animal. This is in line with
previous results from comparable experiments with DEN
as a tumor inducer [32-34]. For a detailed list of the
Figure 1 Cytotoxicity and cell growth inhibition by atorvastatin
in vitro. A. Effects of different concentrations of atorvastatin on
mouse hepatoma cells from lines 53.2b, 55.1c, 70.4 and Hepa1c1c7
after 24 h of treatment, as analyzed by the Alamar blue and neutral
red uptake assays. B. Growth curves of cell cultures in the presence
of atorvastatin. Representative data from 1 out of 4 experiments are
shown as mean + SD of n = 6 technical replicates.
Figure 2 Effects of atorvastatin (AS) treatment (0.1% in diet)
in vivo. A. Diminished weight gain in atorvastatin-treated mice.
Mean + SD (n = 24-25) are shown. B. Increased liver weight and liver
to body weight ratios in atorvastatin-treated mice. C. Reduction of
plasma cholesterol and liver 4β-hydroxycholesterol levels. Mean + SD
(n = 5; 5 randomly selected mice per group) are shown. Statistical
significance (p < 0.05) is indicated by asterisks.
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the Additional file 1: Table S1. As also expected from
previous studies, the vast majority (>95% by number
and volume fraction) of the resulting tumors after
6 months were basophilic, E-cadherin-expressing and
glutamine synthetase-deficient hepatocellular adenoma
(data not shown; for representative immunostainings
see Figure 3A). These characteristics are hallmarks of
mouse liver adenoma with activated MAPK signaling;
e.g. see [48]. Accordingly, mutation analyses revealed
that 20 out of 26 analyzed tumors (77%) contained activatingFigure 3 Expression of the atorvastatin (AS) uptake transporters Oatp
of OATP1A4 and OATP1B2 protein in tumor tissue, as detected by immuno
not expressed in the tumors) and E-cadherin (EC, overexpressed in the tum
blotting. Abbreviations: t, tumor; n, normal tissue. C. Diminished expression
diagrams). Mean + SD (n = 5-6) is shown. Statistical significance (p < 0.05
(encoding E-cadherin) is shown. Data from atorvastatin-treated livers are
(not shown). D. Levels of atorvastatin and hydroxyatorvastatin in normalmutations in either Codon 61 of Ha-ras or Codon 637
of B-raf (Table 1), encoding key players in the MAPK
cascade. Accordingly, Ha-ras-mutated tumors were strongly
positive for the phosphorylated active MAPK downstream
kinase ERK1/2 (data not shown).
Quantification of the hepatic tumor volume fractions
(Figure 4A) as well as the calculation of liver tumor multipli-
cities (Figure 4B) in the two groups revealed that no
significant differences were present between atorvastatin-
treated and control mice (for details please also refer to
the Additional file 1: Table S1). However, variances of1a4 and Oatp1b2 in mouse liver tumors. A. Diminished expression
histochemistry. For comparison, staining for glutamine synthetase (GS,
ors) is shown. B. Validation of protein expression results by Western
of Oatp1a4 (Slco1a4) and Oatp1b2 (Slco1b2) mRNAs in tumors (left
) is indicated by asterisks. For comparison, expression of Cdh1 mRNA
depicted; comparable results were obtained with untreated livers
liver and liver tumors (n = 13-16).
Table 1 Results of mutation analysis
Mutation/AA exchange No. of tumors
Ha-ras Cod. 61 Q ➔ R 7
Ha-ras Cod. 61 Q ➔ L 1
Ha-ras Cod. 61 Q ➔ K 4
Ha-ras Cod. 61 Q ➔ H 0
B-raf Cod. 637 V ➔ E 8
None detected 6
In total, 26 tumors were analyzed for mutations in Ha-ras or B-raf.
Note: The absence of Ha-ras or B-raf mutations in a tumor does not preclude
activation of MAPK signaling in this tumor driven by other genetic alterations.
Figure 4 Lack of atorvastatin effects on the growth of
N-nitrosodiethylamine-induced mouse liver tumors.
A. Tumor volume fraction of control and atorvastatin-treated mice,
as quantified by the analysis of glucose-6-phosphatase-altered
lesion. B. Projected tumor multiplicity. Individual data from n = 24-25
mice per group are shown together with the corresponding box
charts. C. Distribution of tumor volume fraction between mice from
the two groups. Mice were grouped into the following responder
classes according to their hepatic tumor volume fractions: I, tumor
volume fraction <10%; II, 10-15%; III, 15.01-20%; IV, 20.01-25%; V,
25.01-30%; VI, 30.01-35%; VII, 35.01-40%; VIII, 40.01-45%; IX, 45.01-50%;
X, 50.01-60%; XI, >60%. The atorvastatin group has a higher percentage
of weak responders (class I), but also a higher percentage of strong
responders (classes X and XI). D. Size class distribution of tumor
multiplicity. Tumors were grouped into the following size classes:
I, 0.05-0.25 mm diameter; II, 0.26-0.5 mm; III, 0.51-1.00 mm; IV,
1.01-2.00 mm; V, 2.01-6.5 mm; VI, >6.5 mm. Mean + SEM (n = 24-25)
is shown. Statistical significance (p < 0.05) is indicated by asterisks. Very
big tumors are exclusively observed in the atorvastatin group.
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with the significantly higher variance in the atorvastatin
group (p = 0.002; Bartlett’s test). Therefore, some differ-
ences were visible when mice were grouped into “re-
sponder classes”, according to their individual tumor
burden (Figure 4C): with atorvastatin treatment, there
were, on the one hand, comparably many weak responders
with a hepatic tumor volume fraction of <15%. On the
other hand, very strong responders with a hepatic tumor
volume >50% were exclusively present in the atorvastatin-
treated group. Similarly, tumors of the biggest size class,
with a diameter of >6.5 mm, were observed in atorvastatin-
treated livers only (Figure 4D). Tumor volume fraction
values were normally distributed within the control group,
but not in the atorvastatin group (p = 0.026; Shapiro-Wilk
test). Altogether, this indicates a broader distribution of
tumorigenic response in mice treated with atorvastatin, as
compared to control mice. However, these effects of atorva-
statin did not alter the overall mean tumor response of the
population, which was not distinguishable from controls.
Expression of atorvastatin uptake transporters and
atorvastatin levels in tumors
Atorvastatin is taken up into hepatocytes by means of
the organic anion transporters OATP1A4 and OATP1B2
[49]. To check whether inefficient uptake of atorvastatin
might have caused the lack of efficacy of the drug on
tumor development, the expression of these two trans-
porters in normal liver and liver tumors was analyzed by
immunohistochemistry, Western blotting, and real-time
RT-PCR. The results are presented in Figure 3 and dem-
onstrate a marked reduction of both transporters in liver
tumor tissue, as compared to surrounding normal hepa-
tocytes. Of note, OATP1B2 immunoreactivity was pref-
erentially located in perivenous hepatocytes surrounding
the central veins (Figure 3A). Our results are therefore
in line with previous findings that mouse liver tumors
with activated MAPK lack the expression of many ‘peri-
venous’ genes [48]. The down-regulation of the two
transporters might indicate that the uptake of atorva-
statin into tumor cells is reduced. Thus, the levels of
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were analyzed by mass spectrometry in normal liver
and tumor tissue (Figure 3D). Levels of both the drug
and its metabolite were reduced in the tumors, but
the effect slightly failed our criteria for statistical sig-
nificance (p = 0.052 for atorvastatin and p = 0.068 for
hydroxyatorvastatin, respectively).
Discussion
Mouse liver tumors with an activated MAPK signaling
pathway have been extensively characterized; they show
high expression levels of cholesterol-synthesizing enzymes
along with a down-regulation of the main cholesterol-
metabolizing enzyme and possess elevated levels of chol-
esterol [32,33]. Assuming that the metabolic pathways
active in a certain type of tumor are beneficial for their
growth, these tumors appear suited for a preventive
approach based on a cholesterol-lowering compound
such as atorvastatin. Possible beneficial effects of statin
treatment regarding the formation of HCC are controver-
sially discussed (see Background section). The present
data conclusively show that DEN-induced tumor develop-
ment in male C3H/HeN mice is not beneficially affected
by treatment with atorvastatin. This is in line with the
lack of tumor-inhibiting properties of atorvastatin in a
mouse model of TSC2-related liver hemangioma [29],
but not with data obtained with a MYC-driven HCC
mouse model where atorvastatin acted as a tumor-
preventive compound [25].
In principle, a lack of treatment efficacy might always
be related to a too low dose of the respective agent. In
the present study, 0.1% atorvastatin in the diet was able
to slightly reduce the weight gain of the mice and to in-
duce elevated liver weights, indicating that the max-
imum tolerated dose of the drug has been chosen for
the experiment and that results obtained with higher
dosing would always be questionable due to unspecific
toxicity of the compound. Moreover, pharmacological ef-
ficacy of the drug was shown by a significant reduction
of cholesterol levels in the treated population. The ob-
served degree of serum cholesterol reduction is within
the range of what is expected at therapeutic statin doses
in humans [50]. Moreover, the in vitro experiments,
where the different cell lines showed variable responses to
atorvastatin treatment despite similar levels in cholesterol-
synthesizing enzymes, suggest that effects other than
HMGCR inhibition might contribute to the growth-
inhibitory effect of the drug. Of note, it has been pub-
lished that tumor-inhibitory effects of lovastatin even
occur in the absence of measurable effects on choles-
terol levels [28].
The daily food intake has not been measured during
the present study. However, when calculating with pub-
lished average values of a food intake of 5 g per mouseof 30 g body weight [51], the total oral uptake of atorva-
statin in our experiment was approximately 167 mg/kg
body weight/day. This is considerably higher than in the
MYC-HCC experiment by [25], where the drug had been
administered three times per week at 100 mg/kg body
weight, which led to an inhibition of tumor growth. In
synopsis, all these parameters indicate that the selected
atorvastatin dose was not too low to produce relevant
effects. The differences between our results and the pre-
vious study with MYC-induced HCCs [25] might result
from the differences between the physiology of trans-
genic MYC-driven HCCs and our chemically induced
tumors. Differences between mouse strains might also
play a role in the response to atorvastatin treatment. Un-
fortunately, no information about the genetic back-
ground of the mice is provided in [25]. Moreover, the
low number of only 5 animals per group in the previous
study [25] hampers statistical evaluation and interpret-
ation of these results.
In humans, atorvastatin is mainly metabolized by cyto-
chrome (CYP) P450 3A4 [52]. Accelerated metabolism
of the drug in the tumor cells might also be responsible
for the lack of treatment efficacy in our experimental
system. Mouse liver tumors with an activated MAPK
pathway show de-regulated, mostly diminished, mRNA
expression of various CYPs. Enzymes from the Cyp3a
family, however, are not significantly altered in MAPK-
activated mouse liver tumors, as compared to normal
tissue [32,33]. This indicates that major alterations in
the metabolism of atorvastatin are not to be expected in
the tumor cells.
An inefficient uptake of the drug into the tumor cells
might explain also the lack of atorvastatin efficacy in our
experiment. We show that organic anion transporters
involved in the uptake of atorvastatin, namely Oatp1b2
(Slco1b2) and Oatp1a4 (Slco1a4) [49], are strongly down-
regulated in the tumors at the mRNA and protein
levels. Studies with human HCC samples have revealed
the down-regulation of OATP1B1 [53,54], the human
atorvastatin-transporting protein [49]. In view of this
fact, it is tempting to speculate that human hepatocel-
lular tumors might exhibit a reduced ability to take up
atorvastatin and probably also other structurally re-
lated statins. This scenario implies that statins might
not be effective in tumor cells when administered at
the therapeutic dose, thus arguing against the pro-
posed protective effect of statins, given the fact that
the putative tumor-inhibiting properties of statins are
based on direct effects of the drug on tumors cells, not
on indirect effects involving statin effects on tumor-
surrounding non-tumorous cells. However, the ob-
served reduction of atorvastatin levels in mouse liver
tumors is not very pronounced. Therefore, it seems ra-
ther unlikely that the apparent lack of tumor inhibition
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ished uptake of the drug into the tumors.
In summary, present data challenge the idea that atorva-
statin inhibits tumor development in the liver. Nonetheless,
it has to be noted that results from animal experiments
cannot be transferred to the situation in humans with abso-
lute certainty, in this particular case for example due to
possible species differences in tumor genetics and biology,
and/or due to the much higher interindividual variability in
the human population, as compared to inbred mouse
strains. However, in the absence of unequivocal epidemio-
logical data, results from animal experimentation are an
important and indispensable source of information.
Conclusions
The present data provide substantial evidence that ator-
vastatin does not beneficially influence tumor growth in
mouse liver and thereby challenge the hypothesis that
statin use might protect against hepatocellular cancer.
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